Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding

Baron Capital's Q2 2026 investor letter for the Baron Focused Growth Fund discusses the fund's performance and investment strategy. The fund achieved a 13.26% gain, slightly below the Russell 2500 Growth Index's 24.02% return. The fund's underperformance was attributed to concerns over AI's impact on portfolio businesses and underexposure to AI infrastructure.

Despite this, the Fund's companies demonstrated strong revenue growth and improved margins through better client engagement and product offerings. Many stocks are considered undervalued, and companies are actively repurchasing shares, increasing investor confidence. The Fund is viewed favorably due to favorable market conditions and strong balance sheets, with inflation and interest rates anticipated to remain stable.

Baron Focused Growth Fund has historically outperformed its benchmark over 3, 5, and 10 years, delivering significant excess returns with lower market risk. This is attributed to the Fund's research-driven investment approach. The Fund remains committed to long-term investing in growth-oriented businesses, employing a balanced portfolio to manage risk and potentially enhance returns.

One notable holding in the Fund's 2026 portfolio is IDEXX Laboratories, Inc. (NASDAQ:IDXX), a leading provider of diagnostics to the veterinary industry. IDEXX Laboratories, Inc. (NASDAQ:IDXX) closed at $562.20 per share on August 19, 2026, with a market capitalization of $44.29 billion. The company posted a 1-month return of 4.23%, but its shares declined by 11.19% over the past 52 weeks.

In its Q2 2026 letter, Baron Focused Growth Fund noted that IDEXX Laboratories, Inc. (NASDAQ:IDXX) is not among the 40 Most Popular Stocks Among Hedge Funds. The Fund believes certain AI stocks offer greater upside potential and lower downside risk compared to IDEXX Laboratories, Inc. (NASDAQ:IDXX). The Fund acknowledges the company's potential as an investment but favors AI stocks that could benefit significantly from Trump-era tariffs and the onshoring trend.

For those interested in an undervalued AI stock, a free report on the best short-term AI stock is available. Additionally, IDEXX Laboratories, Inc. (NASDAQ:IDXX) is mentioned in another article discussing Jensen Quality Growth Equity Strategy's views on the company. The article also suggests checking the hedge fund investor letters Q2 2026 page for more insights from hedge funds and other leading investors.